Scrying Biotech
Long only, biotech, micro-cap, small-cap

Nektar Fortifies Its Position In Advance Of The Rescheduled FDA Panel On OIC

When I author an opinion piece, I like to keep my followers updated on important changes in the company's fortunes, or to my investment thesis if they occur within a 3-month time frame by expressing thoughts in the comments section of that article. This, however, is not always adequate to the task at hand, and that is now the case where Nektar (NASDAQ:NKTR) is concerned.

I would dearly love to refer you back to that piece, but it's now embargoed for Seeking Alpha Pro readers only. Suffice it to say that Nektar is a burgeoning powerhouse in biotechnology as it morphs from a developmental stage company, into a hybrid, income-generating commercial stage venture.

Crucial to its fortunes,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details